Table 1.
Characteristic* | TNF antagonist monotherapy n=410 | Thiopurine monotherapy n=155 |
P value† | Combination therapy n=105 |
P value‡ |
Mean age, years (SD) | 38.5 (16.2) | 45.6 (16.0) | <0.001 | 41.1 (15.0) | 0.13 |
Female, n (%) | 194 (47.3) | 73 (47.1) | 0.82 | 48 (45.7) | 0.67 |
Race, n (%) | |||||
White | 338 (82.4) | 133 (85.8) | 0.34 | 89 (84.8) | 0.57 |
Asian | 0.001 | 12 (8.8) | <0.001 | 20 (12.9) | 10 (2.4) |
Black | 35 (8.5) | 6 (3.9) | 0.06 | 4 (3.8) | 0.10 |
Ethnicity, n (%) | |||||
Hispanic | 63 (15.4) | 34 (21.9) | 0.05 | 23 (21.9) | 0.05 |
CD, n (%) | 292 (71.2) | 78 (50.3) | <0.001 | 66 (62.9) | 0.06 |
UC/IBD-U, n (%) | 118 (28.8) | 77 (49.7) | 39 (37.1) | ||
Disease Aactivity, n (%) | |||||
Remission | 258 (62.9) | 98 (63.3) | 0.80 | 57 (54.3) | 0.35 |
Mild | 69 (16.8) | 30 (19.4) | 17 (16.2) | ||
Moderate/Ssevere, n (%) | 72 (17.6) | 25 (16.1) | 27 (25.7) | ||
Missing/Uunknown, n (%) | 6 (1.5) | 2 (1.2) | 4 (3.8) | ||
Current smoker, n (%) | 16 (3.9) | 5 (3.2) | 0.70 | 6 (5.7) | 0.41 |
Any comorbidity, n (%) | 114 (27.8) | 49 (31.6) | 0.37 | 40 (38.1) | 0.04 |
Cardiovascular Ddisease, n (%) | 15 (3.7) | 13 (8.4) | 0.02 | 11 (10.5) | 0.004 |
BMI ≥30 kg/m2, n (%) | 62 (15.1) | 23 (14.8) | 0.79 | 25 (23.8) | 0.10 |
Mesalamine/sulfasalazine, n (%) | 43 (10.5) | 61 (39.4) | <0.001 | 27 (25.7) | <0.001 |
Corticosteroid, n (%) | 17 (4.1) | 16 (10.3) | 0.005 | 16 (15.2) | <0.001 |
Severe COVID-19, n (%) | 9 (2.2) | 15 (9.7) | <0.001 | 10 (9.5) | <0.001 |
Death from COVID-19 or related complications, n (%) | 3 (0.7) | 3 (1.9) | 0.36 | 3 (2.9) | 0.17 |
*Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.
†P value comparing thiopurine monotherapy with TNF antagonist monotherapy.
‡P value comparing combination therapy with TNF antagonist monotherapy.
BMI, body mass index; CD, Crohn’s disease; IBD-U, IBD unclassified; TNF, tumour necrosis factor.;